Key result
Adenosine A2B receptor blockade with PSB603 attenuates cardiac fibroblast proliferation in a rat PAH model.
Why the study?
The role of adenosine and the low-affinity adenosine A2B receptor in right ventricular remodeling secondary to pulmonary arterial hypertension remains poorly understood, with conflicting results on therapeutic targeting.
Does adenosine A2B receptor blockade reduce cardiac fibroblast proliferation in a rat model of pulmonary arterial hypertension?
Does adenosine A2B receptor blockade reduce cardiac fibroblast proliferation in a rat model of pulmonary arterial hypertension?
p-value: p=<0.05
Adenosine signaling via the A2B receptor contributes to right ventricular fibroblast overgrowth in PAH, suggesting A2B receptor blockade as a potential therapeutic target to mitigate cardiac remodeling.
May limit fibroblast proliferation in PAH models; leaves open translation to reduced remodeling in vivo or patients.
Sustained pressure overload and fibrosis of the right ventricle (RV) are the leading causes of mortality in pulmonary arterial hypertension (PAH). Although the role of adenosine in PAH has been attributed to the control of pulmonary vascular tone, cardiac reserve, and inflammatory processes, the involvement of the nucleoside in RV remodelling remains poorly understood. Conflicting results exist on targeting the low-affinity adenosine A 2B receptor (A 2B AR) for the treatment of PAH mostly because it displays dual roles in acute vs. chronic lung diseases. Herein, we investigated the role of the A 2B AR in the viability/proliferation and collagen production by cardiac fibroblasts (CFs) isolated from RVs of rats with monocrotaline (MCT)-induced PAH. CFs from MCT-treated rats display higher cell viability/proliferation capacity and overexpress A 2B AR compared to the cells from healthy littermates. The enzymatically stable adenosine analogue, 5′- N -ethylcarboxamidoadenosine (NECA, 1–30 μM), concentration-dependently increased growth, and type I collagen production by CFs originated from control and PAH rats, but its effects were more prominent in cells from rats with PAH. Blockage of the A 2B AR with PSB603 (100 nM), but not of the A 2A AR with SCH442416 (100 nM), attenuated the proliferative effect of NECA in CFs from PAH rats. The A 2A AR agonist, CGS21680 (3 and 10 nM), was virtually devoid of effect. Overall, data suggest that adenosine signalling via A 2B AR may contribute to RV overgrowth secondary to PAH. Therefore, blockage of the A 2A AR may be a valuable therapeutic alternative to mitigate cardiac remodelling and prevent right heart failure in PAH patients.
No takes yet. Share an insight, caveat, or question.
Bessa‐Gonçalves et al. (2023) studied Pulmonary arterial hypertension. Adenosine A2B receptor blockade (PSB603) vs. Control (untreated cells or saline-injected rats) was evaluated on Cardiac fibroblast viability/proliferation and type I collagen production (p=<0.05). Blockage of the adenosine A2B receptor with PSB603 attenuated the proliferative effect of NECA in cardiac fibroblasts isolated from rats with monocrotaline-induced pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: